NCT01196039

A Study of MEMP1972A in the Prevention of Allergen-Induced Airway Obstruction in Patients With Mild Asthma (SOLARIO)

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous MEMP1972A in the Prevention of Allergen-Induced Airway Obstruction in Patients With Mild Asthma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 29 (actual)
• Sponsor: Genentech, Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This Phase II, double-blind, placebo-controlled, randomized, parallel-group study is designed to evaluate the efficacy, safety and tolerability of MEMP1972A when administered to patients by intravenous (IV) infusion for the treatment of allergen-induced asthma.

Conditions

• Asthma

Interventions

Type	Name	Description
DRUG	MEMP1972A	Intravenous repeating dose
DRUG	placebo	Intravenous repeating dose

Timeline

• Start date: 2010-12-01
• Primary completion: 2011-08-01
• Completion: 2012-01-01
• First posted: 2010-09-08
• Last updated: 2016-11-02

Locations

7 sites across 2 countries: Canada, Sweden